Sign inSubscribe

target directory

pd 1 receptor programmed cell death protein 1 clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

1

Directory type

target

Association rule

normalized field

NCT04267146
Source recordAI-normalized

Phase I-II Study of Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade Glioma

The trial investigates the combination of nivolumab, a PD-1 inhibitor, with temozolomide and radiotherapy in pediatric patients with newly diagnosed high-grade gliomas (HGG). Given the limited treatment options for HGG in children, successful outcomes could position this combination as a new standard of care, potentially capturing significant market share in the pediatric oncology space. The trial's completion and subsequent results will be critical for assessing the commercial viability and potential partnerships or licensing opportunities. Competitors in the pediatric oncology market may include other immunotherapies and novel agents targeting HGG, necessitating thorough competitive analysis and diligence on emerging therapies.

AI analysis

Indication: High Grade Glioma

Modality: small molecule

Target: PD-1 receptor (programmed cell death protein 1)

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Source URL: ClinicalTrials.gov

Source updated: Dec 02, 2024

Ingested: Jun 19, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: PD-1 receptor (programmed cell death protein 1)

View original source fields

Condition raw: High Grade Glioma

Condition normalized: High Grade Glioma

Modality raw: small molecule

Modality normalized: small molecule

Target raw: PD-1 receptor (programmed cell death protein 1)

Target normalized: PD-1 receptor (programmed cell death protein 1)

Open report